CSBR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Champions Oncology Inc (CSBR) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has shown revenue growth, its declining net income and EPS, coupled with bearish technical indicators and lack of positive trading signals, suggest limited upside potential in the near term. The lack of recent news, analyst ratings, and significant trading activity further supports a cautious approach.
The technical indicators for CSBR are bearish. The MACD histogram is below 0 and negatively contracting, the RSI is neutral at 46.929, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 5.813, and resistance is at 6.228. The stock closed at 5.99 with no significant price movement.
Revenue increased by 11.46% YoY in Q2 2026, and gross margin improved to 51.7%, up 15.07% YoY.
No recent news, analyst ratings, or significant trading trends from hedge funds, insiders, or Congress. Technical indicators are bearish, and no Intellectia Proprietary Trading Signals are present.
In Q2 2026, revenue increased to $15,035,000 (up 11.46% YoY), but net income dropped to $268,000 (down 63.19% YoY). EPS fell to $0.02 (down 60.00% YoY), while gross margin improved to 51.7% (up 15.07% YoY).
No analyst ratings or price target changes available for CSBR.
